Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron Sucrose in Non-anemic Iron Deficiency and POTS
NCT04855266Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of iron sucrose in postural orthostatic tachycardia syndrome (POTS) and iron deficiency anemia (IDA), sponsored by Mayo Clinic. Primary endpoint: Change in autonomic dysfunction symptoms at 6 months. Planned start Apr 2021; status: withdrawn.
02
Drugs
iron sucrose
03
Conditions
postural orthostatic tachycardia syndrome (POTS)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04855266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855266.